{
    "clinical_study": {
        "@rank": "131177", 
        "arm_group": {
            "arm_group_label": "Avastin regimens", 
            "description": "Patients who are going to receive chemotherapy plus Avastin (bevacizumab)"
        }, 
        "brief_summary": {
            "textblock": "Investigators propose to assess,the safety and tolerability profile (number of participants\n      with adverse events)of bevacizumab (Avastin) when combined with standard chemotherapy as\n      first line treatment of patients with metastatic Breast Cancer."
        }, 
        "brief_title": "Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Nowadays in clinical practice patients with previously untreated metastatic breast cancer\n      often receive taxane-based chemotherapy (paclitaxel or docetaxel) in combination with\n      bevacizumab as it has been shown to increase progression-free survival. There is currently\n      minimal information whether bevacizumab should be given as maintenance therapy after\n      discontinuation of chemotherapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Age \u226518 years\n\n          -  Patients with histologically or cytologically confirmed, HER2-negative, metastatic\n             Breast Cancer\n\n          -  No prior first line treatment for metastatic Breast Cancer\n\n          -  Previous hormonotherapy for metastatic Breast Cancer is allowed\n\n          -  One or more measurable lesions (\u22651cm in diameter with spiral CT scan or \u22652cm    with\n             conventional techniques) according to RECIST criteria\n\n          -  ECOG performance status \u22642\n\n          -  Adequate haematological, renal and hepatic function\n\n          -  Urine protein <2+ (dipstick)\n\n          -  Life expectancy of \u226512 weeks\n\n        Exclusion Criteria:\n\n          -  Previous first line treatment for metastatic colorectal cancer(progression >12 months\n             after the end of adjuvant treatment)\n\n          -  Previous radiotherapy to target lesions\n\n          -  Patients with brain metastases and/or cancerous meningitis\n\n          -  Presence or history of other neoplasm except properly treated basal cell skin cancer\n             or in situ cervical carcinoma\n\n          -  Patients participating in interventional clinical trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Clinics for cancer prevention"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978977", 
            "org_study_id": "CT/10.17"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "mBC", 
            "HER2 negative", 
            "Chemotherapy", 
            "Anti-angiogenic agent", 
            "Bevacizumab", 
            "1st Line"
        ], 
        "lastchanged_date": "November 3, 2013", 
        "location": [
            {
                "contact": {
                    "email": "evamaragoud@gmail.com", 
                    "last_name": "Eva Maragkoudaki", 
                    "phone": "+302810392570"
                }, 
                "facility": {
                    "address": {
                        "city": "Heraklion", 
                        "country": "Greece", 
                        "state": "Crete"
                    }, 
                    "name": "University Hospital of Crete, Dep of Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Dimitris Mavrudis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Stylianos Kakolyris, MD"
                }, 
                "contact_backup": {
                    "last_name": "Nikolaos Xenidis, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Alexandroupolis", 
                        "country": "Greece"
                    }, 
                    "name": "University General Hospital of Alexandroupolis, Dept. of Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Stelios Kakolyris, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nikos251@yahoo.gr", 
                    "last_name": "Nikos Fytrakis", 
                    "phone": "2107715690"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "Air Forces Military Hospital of Athens"
                }, 
                "investigator": {
                    "last_name": "Nikos Kentepozidis, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Stylianos Giassas, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece"
                    }, 
                    "name": "\"IASO\" General Hospital of Athens"
                }, 
                "investigator": {
                    "last_name": "Stylianos Giassas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nikolaos Ziras, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Piraeus", 
                        "country": "Greece"
                    }, 
                    "name": "\"Metaxa's\" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Nikolaos Ziras, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ioannis Mpoukovinas, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Thessaloniki", 
                        "country": "Greece"
                    }, 
                    "name": "\"Theagenion\" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology"
                }, 
                "investigator": {
                    "last_name": "Ioannis Mpoukovinas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_groups": "1", 
        "official_title": "Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy Plus Bevacizumab in Women With HER2-Negative Metastatic Breast Cancer. An Observational Study.", 
        "overall_contact": {
            "email": "georgulv@otenet.gr", 
            "last_name": "Vassilis Georgoulias, MD", 
            "phone": "+302810392750"
        }, 
        "overall_official": {
            "affiliation": "Hellenic Oncology Research Group", 
            "last_name": "Vassilis Georgoulias, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Greece: National Organization of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "In this observational study investigators are going to assess standard schedules  in which administration was every 2 or 3 weeks", 
            "measure": "Number of Participants with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Every 2 or 3 weeks up to 12 or 18 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978977"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "In this observational study investigators are going to assess standard schedules in which the disease evaluation was performed every 3 or 6 weeks", 
                "measure": "Number of Participants with Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Disease evaluation at Week 3 or at week 6"
            }, 
            {
                "measure": "Percentage of Patients with Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Patients Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Hellenic Oncology Research Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hellenic Oncology Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}